Teva Secures Third Credit Rating Upgrade to BBB-, Solidifying Investment-Grade Status
Event summary
- S&P Global Ratings upgraded Teva’s long-term issuer credit rating to BBB- from BB+ on September 4, 2026, marking the third credit rating upgrade in recent months.
- Teva now holds investment-grade credit ratings from all major agencies (S&P, Fitch, Moody’s).
- S&P cited Teva’s sustainable growth prospects in branded products, stabilized generics business, and late-stage pipeline assets as key factors for the upgrade.
- Teva’s CFO Eli Kalif attributed the upgrades to strong execution of the company’s Pivot to Growth strategy and reduced debt.
The big picture
Teva’s triple credit rating upgrade reflects a strategic pivot toward growth and financial discipline, aligning with broader industry trends of debt reduction and portfolio optimization. The upgrades enhance Teva’s ability to invest in innovation and expand its biopharmaceutical portfolio, positioning it for long-term value creation in a competitive market.
What we're watching
- Debt Management
- How Teva will allocate its enhanced financial flexibility to further reduce debt and invest in growth.
- Pipeline Execution
- Whether Teva can sustain its momentum in developing and commercializing late-stage assets.
- Market Positioning
- The pace at which Teva can strengthen its position in branded products and biosimilars amid competitive pressures.
Related topics